Physician profile
Nathaniel Barnes
NPI 1033119516
$331,377.04
in general payments reported to CMS, 2019-2025
38 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $14K · 2021: $12K · 2022: $52K · 2023: $71K · 2024: $96K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Travel and Lodging: $29K · Consulting Fee: $20K · Food and Beverage: $7,837 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,565.77 |
| Travel and Lodging | $29,000.00 |
| Consulting Fee | $20,240.00 |
| Food and Beverage | $7,837.10 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $187,609.64 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $97,913.83 | 2023-2025 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $26,374.18 | 2021-2022 | |
| Pfizer INC. | $14,083.70 | 2019-2025 | |
| Boston Scientific Corporation | $1,854.79 | 2019-2024 | Lithovue, Rezum Generator, Lithoclast |
| Coloplast Corp | $909.86 | 2019-2025 | Porges Coloplast, Speedicath |
| Agiliti Surgical, INC. | $322.77 | 2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Dornier Medtech America, INC | $234.72 | 2019 | |
| Astellas Pharma Global Development | $193.63 | 2019-2024 | Xtandi |
| Teleflex LLC | $181.50 | 2021-2022 | |
| Neotract INC. | $165.75 | 2019 | |
| Olympus America INC. | $162.42 | 2020-2025 | Itind System |
| Abbvie INC. | $158.65 | 2022-2025 | Lupron Depot |
| C. R. Bard, INC. & Subsidiaries | $140.74 | 2019-2021 | |
| Novo Nordisk INC | $116.11 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.